Higher levels of PA1-nuc protein in 243 relapse-free patients, compared with 21 relapsed patients, and the significant PA1 correlation with non-aggressive clinicopathological parameters, may suggest that PA1 has tumor-suppressor-like activity and functions as a candidate tumor suppressor in ER+/HER2- subtype. This evidence concerns the gene ERBB2 and neoplasm.